LOKELMATM Sodium Zirconium Cyclosilicate

SWIFT* K+ REDUCTION AFTER ONE HOUR.1,2
SUSTAINED K+ CONTROL FOR UP TO ONE YEAR
WHEN USED AS A MAINTENANCE THERAPY.†1
NOW IN YOUR HANDS.
New, highly-selective LOKELMA (sodium zirconium cyclosilicate)
is indicated for the treatment of hyperkalaemia in adult patients1

*In an emergency situation, standard of care should be used in line with local or national guidelines
Clinical trials with LOKELMA have not included exposure longer than one year

About Hyperkalaemia

The consequences of hyperkalaemia can be life threatening5,6

Hyperkalaemia is often asymptomatic and can progress rapidly.5

Severe hyperkalaemia is a medical emergency that may cause arrhythmia and sudden death.*5

Elevated K+ is a significant predictor of mortality in patients with critical illnesses or conditions like chronic kidney disease, diabetes mellitus and heart failure.7-9

*In an emergency situation, standard of care should be used in line with local or national guidelines.

Hyperkalaemia and Mortality Risk

Higher serum K+ levels and comorbidities increase the mortality risk associated
with hyperkalaemia5,18

Risk of all-cause mortality by serum K+ level and comorbidities in US electronic health record data. Spline analysis adjusted for covariates, showing serum K+ as a continuous variable with all-cause mortality18

Predicted probability of mortality
Predicted probability of mortality

Adapted from Collins AJ, et al. Am J Nephrol. 2017;46:213-221.